Literature DB >> 10764955

Immunohistochemical localization and distribution of VIP/PACAP receptors in human lung.

R Busto1, J C Prieto, G Bodega, J Zapatero, I Carrero.   

Abstract

VIP and PACAP are distributed in nerve fibers throughout the respiratory tract acting as potent bronchodilators and secretory agents. By using RT-PCR and immunoblotting techniques, we have previously shown the expression of common VIP/PACAP (VPAC(1) and VPAC(2)) and specific PACAP (PAC(1)) receptors in human lung. Here we extend our aims to investigate by immunohistochemistry their localization and distribution at this level. A clear immunopositive reaction was obtained in human lung sections by using either anti-VPAC(1) or -VPAC(2) receptor antibodies but not with anti-PAC(1) receptor antibody. However, PAC(1) receptor (and VPAC(1) and VPAC(2) receptors) could be identified in lung membranes by immunoblotting which supports that the PAC(1) receptor is expressed at a low density. Both VPAC(1) and VPAC(2) receptors showed similar immunohistochemical patterns appearing in smooth muscle cells in the wall of blood vessels and in white blood cells (mainly in areas with inflammatory responses). The results agree with previous evidence on the importance of both peptides in the immune system and support their anti-inflammatory and protective roles in lung.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10764955     DOI: 10.1016/s0196-9781(99)00202-8

Source DB:  PubMed          Journal:  Peptides        ISSN: 0196-9781            Impact factor:   3.750


  12 in total

1.  PACAP immunoreactivity in human malignant tumor samples and cardiac diseases.

Authors:  Z Szanto; Zs Sarszegi; D Reglodi; J Nemeth; K Szabadfi; P Kiss; A Varga; E Banki; K Csanaky; B Gaszner; O Pinter; Zs Szalai; A Tamas
Journal:  J Mol Neurosci       Date:  2012-05-31       Impact factor: 3.444

Review 2.  Newer approaches and novel drugs for inhalational therapy for pulmonary arterial hypertension.

Authors:  Ali Keshavarz; Hossam Kadry; Ahmed Alobaida; Fakhrul Ahsan
Journal:  Expert Opin Drug Deliv       Date:  2020-02-19       Impact factor: 6.648

3.  Pharmacological properties of Chinese hamster ovary cells coexpressing two vasoactive intestinal peptide receptors (hVPAC1 and hVPAC2).

Authors:  Ingrid Langer; Nathalie Gaspard; Patrick Robberecht
Journal:  Br J Pharmacol       Date:  2006-06-19       Impact factor: 8.739

Review 4.  GPCRs in pulmonary arterial hypertension: tipping the balance.

Authors:  Jean Iyinikkel; Fiona Murray
Journal:  Br J Pharmacol       Date:  2018-04-17       Impact factor: 8.739

5.  Vasoactive intestinal peptide as a new drug for treatment of primary pulmonary hypertension.

Authors:  Ventzislav Petkov; Wilhelm Mosgoeller; Rolf Ziesche; Markus Raderer; Leopold Stiebellehner; Karin Vonbank; Georg-Christian Funk; Gerhard Hamilton; Clemens Novotny; Bernhard Burian; Lutz-Henning Block
Journal:  J Clin Invest       Date:  2003-05       Impact factor: 14.808

6.  Activation of VPAC1 receptors by VIP and PACAP-27 in human bronchial epithelial cells induces CFTR-dependent chloride secretion.

Authors:  Renaud Dérand; Alicia Montoni; Laurence Bulteau-Pignoux; Thierry Janet; Bertrand Moreau; Jean-Marc Muller; Frédéric Becq
Journal:  Br J Pharmacol       Date:  2004-01-26       Impact factor: 8.739

7.  Examination of PACAP-Like Immunoreactivity in Urogenital Tumor Samples.

Authors:  Andrea Tamas; Andras Javorhazy; Dora Reglodi; Donat Peter Sarlos; Daniel Banyai; David Semjen; Jozsef Nemeth; Beata Lelesz; Daniel Balazs Fulop; Zalan Szanto
Journal:  J Mol Neurosci       Date:  2015-10-10       Impact factor: 3.444

8.  Vasodilatory effect of the stable vasoactive intestinal peptide analog RO 25-1553 in murine and rat lungs.

Authors:  Jun Yin; Liming Wang; Ning Yin; Arata Tabuchi; Hermann Kuppe; Gerhard Wolff; Wolfgang M Kuebler
Journal:  PLoS One       Date:  2013-09-19       Impact factor: 3.240

Review 9.  VIP/PACAP signaling as an alternative target during hyperoxic exposure in preterm newborns.

Authors:  Q Thaçi; S Reçica; I Kryeziu; V Mitrokhin; A Kamkin; R Sopi; N Hadzi-Petrushev; M Mladenov
Journal:  Physiol Res       Date:  2021-06-01       Impact factor: 1.881

Review 10.  PACAP38 and PAC1 receptor blockade: a new target for headache?

Authors:  Eloisa Rubio-Beltrán; Edvige Correnti; Marie Deen; Katharina Kamm; Tim Kelderman; Laura Papetti; Simone Vigneri; Antoinette MaassenVanDenBrink; Lars Edvinsson
Journal:  J Headache Pain       Date:  2018-08-07       Impact factor: 7.277

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.